From Tier Table Database
CDC Office of Public Health Genomics (OPHG) conducts horizon scanning (a systematic research method to find and follow novel technologies appearing in the literature) to identify and track the progress of genomic tests as they move from research into clinical and public health practice. As an aid in organizing horizon scanning results, OPHG ranks genomic tests, and family health history applications, by levels of evidence. See detail.
| Disease/Disorder | Test to be Assessed | Intended Use | Tier Classified | Detail |
|---|---|---|---|---|
| Acute coronary syndrome | CYP2C19 | Pharmacogenomic for ticagrelor | Tier 2  | |
| Acute coronary syndrome managed with percutaneous coronary intervention | CYP2C19 | Pharmacogenomic for prasugrel | Tier 2 | |
| Non-ST-segment elevation acute coronary syndrome, ST-elevation myocardial infarction, myocardial infarction, stroke, peripheral arterial disease | CYP2C19 | Pharmacogenomic for clopidogrel | Tier 2 | |
| Atrial fibrillation | CYP2D6 | Pharmacogenomic for propafenone | Tier 2 | |
| Chronic heart failure, left ventricular dysfunction following myocardial infarction, hypertension | CYP2D6 | Pharmacogenomic for carvedilol | Tier 2 |
.png)
No hay comentarios:
Publicar un comentario